Tranexamic acid 250mg Capsules
Tranexamic acid 500mg Capsules
Each capsule contains:
Tranexamic Acid BP 250mg
Size '2' hard gelatin capsule having yellow body and green cap.
Each capsule contains:
Tranexamic Acid BP 500mg
White compacted powder filled in size '0' hard gelatin capsule with blue cap and grey body
Administration: May be taken with or without food
Pregnancy :Category B
Storage: Store below 25°C; Keep out of reach of children.
Missed dose: Take the missed dose as soon as you remember; Skip the missed dose if it is almost time for your next scheduled dose; Do not take extra medicine to make up the missed dose.
Pharmacotherapeutic Group: Anti-fibrinolytic agent
Anti-fibrinolytic agent: Tranexamic acid is an antifibrinolytic agent that competitively inhibits the activation of plasminogen to plasmin and prevents the degradation of fibrin clot. At much higher concentrations it is a non-competitive inhibitor of plasmin.
In melasma: Melasma is tan or dark skin coloration. It is the hyperpigmentation due to overproduction of melanin. Tranexamic acid interferes with tyrosinase enzyme and inhibits melanin synthesis.
Absorption: Absorbed from the GI tract; peak plasma concentrations after 3 hr (oral); Bioavailability: 30-50%, unaffected by food intake.
Distribution: Widely throughout the body. Protein-binding: Very low. Crosses the placenta, blood brain barrier and distributed into breast milk.
Excretion: Urine (as unchanged drug); Elimination half-life: 2hr.
Dermal, epidermal and mixed melasma; Dermal erythema; Vaginal bleeding; Menorrhagia; Dentistry; Hemophilia; Injuries and trauma; Surgery; Nasal bleeding.
As anti-fibrinolytic agent: 500mg two to three times daily.
In melasma: 250mg twice daily for 3 months.
Severe renal failure, Hypersensitivity, Thromboembolic disease, subarachnoid bleeding, Colour vision disorders, History of convulsion, Disseminated intravascular coagulation; consumption coagulopathy.
Mild to moderate renal impairment, Irregular menstrual bleeding, Previous history of thromboembolic disease, Haematuria, Oral contraceptives.
ADVERSE DRUG REACTIONS
Diarrhoea, nausea, vomiting, disturbances in colour vision, giddiness, thromboembolic events.
Potentially Fatal: Increased risk of thrombus formation with estrogens, Factor IX complex concentrates or anti-inhibitor coagulant concentrates. Increased risk of fatal thrombotic complications with tretinoin in acute promyelocyticleukaemia.
TRANCAP 250: Each box contains 10 blister packs of 10 capsules per strip
TRANCAP 500: Each box contains 10 blister packs of 10 capsules per strip